Caribou Biosciences is gunning for a Phase 3 pivotal trial start in 2025 for lead candidate CB-010, after cutting its CAR-NK preclinical activities to focus exclusively on developing CB-010 and two additional allogeneic CAR-T therapies.

PwC's Medical Cost Trend: Behind The Numbers 2025 report offers details on the key 'inflators' and 'deflators' impacting medical spending next year. The key inflator? You guessed it, weight loss drugs.

Oral conversations with the FDA about trial design and protocol can lead to questions, and answers, that help drug developers avoid costly surprises and misunderstandings.

Industry veteran James Sapirstein, CEO of Entero Therapeutics, discusses the company's lead candidate, a treatment for celiac disease, and makes the case for investors and Big Pharma to step up and help bring it across the finish line.

Volastra Therapeutics is a drug discovery and development leader in the emerging field of chromosomal instability, a phenomenon that can determine how certain solid tumor cancer cells replicate and grow.

Project Data Sphere, an open access data sharing initiative, is expanding into closed access preclinical research and developing AI models that can benefit drug developers.

Nonprofit research foundations can offer scientific expertise and support for biopharmaceutical drug development and clinical programs, helping companies improve new and existing drugs for women.

Otsuka Precision Health, a new subsidiary focused on digital therapeutics and other tech-enabled solutions for patients, is a continuation of the company's broader mission described by an Otsuka executive in the pages of Life Science Leader eight years ago.

For Nuvalent CEO James Porter, physician intelligence is more important than artificial intelligence in discovering and developing new therapies that tackle key unmet needs among cancer patients.